EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparative analysis of andexanet alfa and prothrombin complex concentrate in reversing anticoagulation by rivaroxaban ex vivo

Farahnaz Rayatdoost, Katharina Deventer, Rolf Rossaint, Herbert Schöchl, Oliver Grottke

British Journal of Anaesthesia · 2024-02 · 132 (2) · 251-259

DOI: 10.1016/j.bja.2023.10.018 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift British Journal of Anaesthesia, 2024-02. Verfasst von Farahnaz Rayatdoost und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anaesthesiology, RWTH Aachen University Hospital, Aachen, Germany. Hauptthemen laut MEDLINE: Hemostatics, Rivaroxaban. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Boehringer Ingelheim.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The comparative effectiveness of the specific antidote andexanet alfa vs the nonspecific therapy four-factor prothrombin complex concentrates (4F-PCCs) as reversal agents for direct factor Xa (FXa) inhibitors in severely bleeding patients is unclear. We hypothesised that specific reversal using andexanet alfa would be more effective than a high dose of PCC (50 IU kg-1) for reversing the FXa inhibitor rivaroxaban. METHODS: The reversal potential of andexanet alfa, various 4F-PCCs, and activated PCC was investigated ex vivo in human blood anticoagulated with rivaroxaban (37.5, 75, 150, and 300 ng ml-1) using a panel of coagulation parameters, including conventional coagulation assays, thrombin generation, and a newly developed viscoelastometric device. We simulated in vivo conditions of coagulation activation and fibrin formation using flow chamber experiments of thrombogenicity potential under arterial flow conditions. RESULTS: The 4F-PCCs normalised clotting profiles only at low rivaroxaban concentrations, whereas andexanet alfa and activated PCC significantly shortened clotting time at all rivaroxaban concentrations. Only andexanet alfa restored thrombin generation to baseline. Flow chamber results showed that various 4F-PCCs concentration-dependently restored clot formation. CONCLUSIONS: In contrast to thrombin generation measurements, haemostatic reversal of rivaroxaban using high-dose 4F-PCCs exhibited similar efficacy as andexanet alfa in flow chamber experiments. The haemostatic effects of 4F-PCCs and andexanet alfa in the context of bleeding patients taking FXa inhibitors requires further study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HemostaticsRivaroxabanHumansAnticoagulantsBlood Coagulation FactorsFactor IXFactor XaFactor Xa InhibitorsHemorrhageRecombinant ProteinsThrombin

Stichwörter der Autor:innen

andexanetalfaassayscoagulation testingprothrombin complex concentraterivaroxabanthrombin generationviscoelastometry

Substanzen

AnticoagulantsBlood Coagulation FactorsFactor IXFactor XaFactor Xa InhibitorsHemostaticsprothrombin complex concentratesPRT064445Recombinant ProteinsRivaroxaban

Autor:innen und Institutionen

  • Department of Anaesthesiology, RWTH Aachen University Hospital, Aachen, Germany.
  • Department of Anaesthesiology and Intensive Care Medicine, AUVA Trauma Centre Salzburg, Paracelsus Medical University, Salzburg, Austria; Ludwig Boltzmann Institute for Traumatology, The Research Centre in Cooperation w…
  • Department of Anaesthesiology, RWTH Aachen University Hospital, Aachen, Germany. Electronic address: ogrottke@ukaachen.de.

Förderung

  • Boehringer Ingelheim

Zitieren

APA

Rayatdoost, F., Deventer, K., Rossaint, R., Schöchl, H., & Grottke, O. (2024). Comparative analysis of andexanet alfa and prothrombin complex concentrate in reversing anticoagulation by rivaroxaban ex vivo. British Journal of Anaesthesia, 132(2), 251-259. https://doi.org/10.1016/j.bja.2023.10.018

Vancouver

Rayatdoost F, Deventer K, Rossaint R, Schöchl H, Grottke O. Comparative analysis of andexanet alfa and prothrombin complex concentrate in reversing anticoagulation by rivaroxaban ex vivo. British Journal of Anaesthesia. 2024;132(2):251-259. doi:10.1016/j.bja.2023.10.018

BibTeX
@article{Rayatdoost2024,
  author = {Rayatdoost, Farahnaz and Deventer, Katharina and Rossaint, Rolf and Schöchl, Herbert and Grottke, Oliver},
  title = {Comparative analysis of andexanet alfa and prothrombin complex concentrate in reversing anticoagulation by rivaroxaban ex vivo},
  journal = {British Journal of Anaesthesia},
  year = {2024},
  volume = {132},
  number = {2},
  pages = {251--259},
  doi = {10.1016/j.bja.2023.10.018}
}
Kostenlos starten →